Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Elias Jabbour,Nicola Gökbuget,Anjali S. Advani,Matthias Stelljes,Wendy Stock,Michaela Liedtke,Giovanni Martinelli,Susan OBrien,Tao Wang,Douglas Laird,Erik Vandendries,Alexander Neuhof,Daniel J. DeAngelo,Hagop M. Kantarjian

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

2018

Elias Jabbour
Nicola Gökbuget
Anjali S. Advani
Matthias Stelljes
Wendy Stock
Michaela Liedtke
Giovanni Martinelli
Susan OBrien
Tao Wang
Douglas Laird
Erik Vandendries
Alexander Neuhof
Daniel J. DeAngelo
Hagop M. Kantarjian

7013Background: MRD negativity is a key prognostic indicator of patient (pt) outcome in ALL and is predictive of improved survival and disease-free status. In the INO-VATE ALL trial (Kantarjian, NE...

Keywords:

Refractory
Minimal residual disease
Oncology
Inotuzumab ozogamicin
Pathology
Lymphoblastic Leukemia
Medicine
Internal medicine
improved survival
MRD Negativity
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations